Table 1 Characteristics of the patients

Median age in years (range)

60 (20–81)

Histology

 PTCL-U

17

27.0

 Anaplastic large cell (ALK-negative)

6 (3)

9.5

 Angioimmunoblastic

10

15.9

 Extranodal NK/T cells

27

42.9

 Enteropathy-associated

1

1.6

 Systemic cutaneous or mycosis fungoides

1

1.6

 Hepatosplenic γδ

1

1.6

Stage

 I-II

24

38.1

 III-IV

39

54.0

B symptoms

26

41.3

Bone marrow involvement

18

28.6

IPI

 Low/Low-intermediate

22/10

34.9/15.9

 High-intermediate/High

16/15

25.4/23.8

PIT

 0/1 factor

12/22

19.0/34.9

 2 factors

14

22.2

 3-4 factors

15

23.8

Primary chemotherapy

 CHOP/ CHOP-like

53

84.1

 Others (IMVP-16, EPOCH and VIDL)

10

15.9

Involved field radiation therapy

15

23.8

Response to primary chemotherapy

 CR/PR

34/7

54.0/11.1

 SD or PD

18

28.6

 Non-measurable

4

6.3

Performance of autologous stem cell transplantation

9

14.3

Treatment-related toxicity

5

7.9